Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novavax, Inc.

https://novavax.com/

Latest From Novavax, Inc.

EU ‘Among World Leaders’ In COVID-19 Vaccination

Vaccination campaigns against the coronavirus in the EU are recovering ground lost in the early days of the pandemic, although the European Commission says “we need to keep up the effort.”

Europe Coronavirus COVID-19

Claims Stream In Under COVAX No-Fault Compensation Program

The WHO indicates that several claim applications have been made under the COVAX no-fault lump-sum compensation program for COVID-19 vaccines. It remains to be seen how the scheme may apply to countries like India, which is also expected to take a call on indemnity to vaccine makers.

Commercial Vaccines

Deal Watch: Pfizer Invests In Spero, Parexel Trades Hands

EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.

Deal Watch Business Strategies

CureVac Still Hopes Variants Could Win Favor For COVID-19 Vaccine

Patients 18-60 had a protection rate of 53%, but there were too few cases among those older than 60 – a crucial subgroup – in HERALD to draw conclusions about the vaccine’s efficacy among older people.

Coronavirus COVID-19 Vaccines
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Liposomes
  • Other Names / Subsidiaries
    • CPL Biologicals Pvt. Ltd. (Joint Venture with Cadila)
    • Isconova AB
    • Novavax AB
UsernamePublicRestriction

Register